Galapagos announces expanded relationship with AstraZeneca

BioFocus DPI to provide drug discovery services to US-site

10-Aug-2007

Galapagos NV announced that its service division, BioFocus DPI, has entered into a new drug discovery collaboration with AstraZeneca . Building upon previously announced drug discovery collaborations between the two companies, this collaboration involves BioFocus DPI performing medicinal chemistry, computational chemistry and supporting biology and ADMET services for AstraZeneca's Infection discovery program based in Boston, US. Total contract value for Galapagos will be EUR 680,000.

This announcement marks the third collaboration between AstraZeneca and BioFocus DPI. In August 2006, Galapagos announced BioFocus DPI's first drug discovery collaboration with AstraZeneca. Under a second program initiated in April 2007, BioFocus DPI is performing chemistry and supporting biology and ADME services for an AstraZeneca hit-to-lead program. While these collaborations focused on AstraZeneca's European-based R&D, the new agreement announced expands BioFocus DPI's drug discovery services to AstraZeneca's US-based R&D.

https://www.bionity.com/en/news/66950/galapagos-announces-expanded-relationship-with-astrazeneca.html